Veterinary Medicines

HIPRABOVIS-4 ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ

Authorised
  • Bovine respiratory syncytial virus, strain Lym-56, Live
  • Bovine viral diarrhoea virus, strain NADL, Inactivated
  • Bovine parainfluenza virus 3, strain SF-4, Inactivated
  • Bovine herpesvirus 1, strain LA, Inactivated
Download as PDF

Product identification

Medicine name:
HIPRABOVIS-4 ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ
Active substance:
  • Bovine respiratory syncytial virus, strain Lym-56, Live
  • Bovine viral diarrhoea virus, strain NADL, Inactivated
  • Bovine parainfluenza virus 3, strain SF-4, Inactivated
  • Bovine herpesvirus 1, strain LA, Inactivated
Target species:
  • Cattle
Route of administration:
  • Intramuscular use
  • Subcutaneous use

Product details

Active substance and strength:
  • Bovine respiratory syncytial virus, strain Lym-56, Live
    100000.00
    50% tissue culture infectious dose
    /
    1.00
    Tablet
  • Bovine viral diarrhoea virus, strain NADL, Inactivated
    1000000.00
    50% tissue culture infectious dose
    /
    0.60
    millilitre(s)
  • Bovine parainfluenza virus 3, strain SF-4, Inactivated
    1000000.00
    50% tissue culture infectious dose
    /
    0.75
    millilitre(s)
  • Bovine herpesvirus 1, strain LA, Inactivated
    10000000.00
    50% tissue culture infectious dose
    /
    1.35
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Cattle
      • Meat and offal
        21
        day
  • Subcutaneous use
    • Cattle
      • Meat and offal
        21
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AH
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Greece
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Complete application (stand-alone)
Marketing authorisation holder:
  • Laboratorios Hipra S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Hipra S.A.
Responsible authority:
  • National Organization For Medicines
Authorisation number:
  • 35067/18-10-1999/K-0114301
Date of authorisation status change: